Printer friendly
Acronymfinder

What does NARI stand for?

NARI stands for NorAdrenaline Reuptake Inhibitor


This definition appears very rarely and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.

See other meanings of NARI

Other Resources:
We have 38 other definitions for NARI in our Acronym Attic

Samples in periodicals archive:

Current leading guidelines from the American Psychiatric Association (APA) and the Canadian Network for Mood and Anxiety Treatments (CANMAT) recommend selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs), as a first-line treatment for depression.
Pipeline candidates fall under major therapeutic classes such as noradrenaline reuptake inhibitors, adrenergic uptake inhibitors, enzyme replacement therapy, dopamine agents, chelating agents and Gamma-amino butyric acid type B (GABA-B) receptor agonist - Analysis of the current and future competition in the global Autistic Disorder market.
Included in this long list are selective serotonin reuptake inhibitors, noradrenaline reuptake inhibitors, nonselective neurotransmitter inhibitors, monoamine oxidase inhibitors, antiepileptic agents, and tramadol and other analgesics.
David Healey, director of the North Wales Department of Psychological Medicine noted the link between the new antidepressants-Selective Serotonin Re-uptake Inhibitors or SSRI'S and Serotonin Noradrenaline Reuptake Inhibitors or SNRI'S--and an increased risk of suicide and violent behaviour in teenagers or children, who were prescribed the drugs.
Pipeline candidates fall under major therapeutic classes such as noradrenaline reuptake inhibitors, adrenergic uptake inhibitors, enzyme replacement therapy, dopamine agents, chelating agents and Gamma-amino butyric acid type B (GABA-B) receptor agonist * Analysis of the current and future competition in the global Autistic Disorder market.
Both short-term and long-term results from the large, comprehensive, international development programme including nearly 4000 adult patients with MDD were presented to the CHMP to support the efficacy of Valdoxan as compared with placebo, selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitor (SNRI) treatments.